Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026
adeno associated virus vectors in gene therapy market forecast
The Business Research Company's Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026
LONDON, GREATER LONDON, UNITED KINGDOM, April 2, 2026 /EINPresswire.com/ -- "The adeno-associated virus (AAV) vectors in gene therapy market are dominated by a mix of global biopharmaceutical companies and specialized gene therapy technology providers. Companies are focusing on advanced vector design, scalable manufacturing platforms, targeted delivery systems, and enhanced regulatory compliance frameworks to strengthen market presence and maintain stringent clinical and ethical standards. Emphasis on safety, transduction efficiency, and integration of digital data management and quality control systems remains central to competitive positioning. Understanding the competitive landscape is essential for stakeholders seeking growth opportunities, technological innovation, and strategic partnerships within the rapidly evolving gene therapy and viral vector development sector.
Which Market Player Is Leading The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market?
• According to our research, Novartis AG led global sales in 2024 with a 2% market share. The gene therapy division of the company, which is directly involved in the adeno-associated virus (AAV) vectors market, provides a wide range of viral vector platforms, gene delivery technologies, manufacturing solutions, and quality control systems that support clinical gene therapy development, precision medicine applications, and regulated biopharmaceutical environments.
Who Are The Major Players In The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market?
Major companies operating in the adeno-associated virus (AAV) vectors in gene therapy market are Novartis AG, F. Hoffmann-La Roche Ltd., Sarepta Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Biogen Inc., Abeona Therapeutics Inc., Oxford BioMedica plc, Sanofi S.A., uniQure N.V., Voyager Therapeutics Inc., Taysha Gene Therapies Inc., Revvity, Inc., Aldevron LLC, 4D Molecular Therapeutics, Neurophth Biotechnology, AGC Biologics, MeiraGTx Holdings plc, LogicBio Therapeutics Inc., Dyno Therapeutics Inc., Astellas Gene Therapies Inc., StrideBio, SIRION Biotech, GenSight Biologics S.A.
How Concentrated Is The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market?
• The market is fragmented, with the top 10 players accounting for 9% of total market revenue in 2024. This level of concentration reflects moderate technological and regulatory entry barriers, driven by complex vector design and manufacturing requirements, compliance with stringent clinical and regulatory standards, high precision in gene delivery and transduction efficiency, and the need for reliability and safety in gene therapy development and biopharmaceutical environments. Leading players such as Novartis AG, F. Hoffmann-La Roche Ltd., Sarepta Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Biogen Inc., Abeona Therapeutics Inc., Oxford BioMedica plc, Sanofi S.A., and uniQure N.V. hold notable market shares through diversified AAV vector platforms, established research and clinical partnerships, global manufacturing and distribution networks, and continuous innovation in gene therapy development and delivery technologies. As demand for advanced viral vector solutions, scalable manufacturing capabilities, and regulatory-compliant gene therapy products grows, strategic collaborations, product innovation, and regional expansion are expected to strengthen the competitive positioning of these leading companies in the market.
• Leading companies include:
o Novartis AG (2%)
o F. Hoffmann-La Roche Ltd. (2%)
o Sarepta Therapeutics Inc. (1%)
o REGENXBIO Inc. (1%)
o Passage Bio Inc. (1%)
o Biogen Inc. (1%)
o Abeona Therapeutics Inc. (1%)
o Oxford BioMedica plc (1%)
o Sanofi S.A. (0.2%)
o uniQure N.V. (0.1%)
Request A Free Sample Of The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Report
https://www.thebusinessresearchcompany.com/sample_request?id=24135&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Mar_PR
Who Are The Key Raw Material Suppliers In The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market?
• Major raw material suppliers in the adeno-associated virus (AAV) vectors in gene therapy market include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Catalent, Inc., GE Healthcare Life Sciences, Fujifilm Diosynth Biotechnologies, WuXi AppTec Co., Ltd., Samsung Biologics Co., Ltd., Bio-Techne Corporation, Sartorius AG, Agilent Technologies, Inc., Cytiva, Genevant Sciences Corporation, Vector Biolabs, Brammer Bio, Paragon Bioservices, Inc., Vigene Biosciences, Inc., Cobra Biologics Ltd., Cell and Gene Therapy Catapult, Polyplus-transfection SA, REPROCELL Inc., OriGene Technologies, Inc.
Who Are The Major Wholesalers And Distributors In The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market?
• Major wholesalers or distributors in the adeno-associated virus (AAV) vectors in gene therapy market include Fisher Scientific International, Inc., VWR International LLC, Medline Industries, LP, Bio-Rad Laboratories, Inc., Carolina Biological Supply Company, Sigma-Aldrich Corporation, Avantor, Inc., Thomas Scientific, Lonza Bioscience Distribution, GenScript Biotech Corporation, Tocris Bioscience, Stemcell Technologies Inc., Acros Organics, Eurofins Scientific SE, Charles River Laboratories International, Inc., PeproTech, Inc., PromoCell GmbH, Enzo Life Sciences, Inc., Takara Bio USA, Inc., PerkinElmer, Inc.
Who Are The Major End Users Of The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market?
• Major end users in the adeno-associated virus (AAV) vectors in gene therapy market include Novartis AG, Pfizer Inc., Johnson & Johnson, Spark Therapeutics, Inc., uniQure N.V., Sarepta Therapeutics, Inc., REGENXBIO Inc., BioMarin Pharmaceutical Inc., Astellas Pharma Inc., GlaxoSmithKline PLC, Beam Therapeutics Inc., Editas Medicine, Inc., Orchard Therapeutics plc, MeiraGTx Holdings plc, Audentes Therapeutics, Inc., Solid Biosciences Inc., Homology Medicines, Inc., Genethon, Oxford BioMedica plc, Freeline Therapeutics Holdings plc, LogicBio Therapeutics, Inc.
What Are The Major Competitive Trends In The Market?
• End-to-End AAV Production Platforms are transforming the market by enhancing scalability, accelerating clinical development, and improving supply chain readiness.
• Example: In January 2024, Forge Biologics expanded its commercial-scale AAV manufacturing facility, integrating cGMP suites, process development, and analytical testing.
• Its integrated infrastructure improves production reliability, reduces turnaround times, and supports clinical-to-commercial programs efficiently.
Which Strategies Are Companies Adopting To Stay Ahead?
• Advancing Engineered Tissue-Specific AAV Capsids To Enhance Targeted Gene Delivery And Therapeutic Precision
• Leveraging Receptor-Targeted Engineered AAV Platforms To Improve Neurological Gene Therapy Delivery
• Expanding Optimized RepCap Plasmid Platforms To Streamline AAV Vector Manufacturing And Process Efficiency
• Integrating Novel Multi-Tissue Targeting AAV Capsids To Strengthen Systemic Gene Therapy Applications
Access The Detailed Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Report Here
https://www.thebusinessresearchcompany.com/report/adeno-associated-virus-avv-vectors-in-gene-therapy-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Mar_PR
Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.
Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company"
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
